{"result": "(\"entity\"<|>CORTISOL<|>EVENT<|>Cortisol is a steroid hormone produced by the adrenal glands, playing a vital role in the body's response to stress and metabolism regulation.)\n##\n(\"entity\"<|>ACTH<|>EVENT<|>Adrenocorticotropic hormone (ACTH) is a hormone produced by the pituitary gland that stimulates the production of cortisol from the adrenal glands.)\n##\n(\"entity\"<|>HIDROCORTISONA<|>EVENT<|>Hydrocortisone is a corticosteroid medication used to treat various conditions by mimicking the effects of cortisol in the body.)\n##\n(\"entity\"<|>IGF-1<|>EVENT<|>Insulin-like growth factor 1 (IGF-1) is a hormone that plays an important role in growth and development, often measured in the context of growth hormone deficiencies.)\n##\n(\"entity\"<|>NEURONTIN<|>EVENT<|>Neurontin, also known as gabapentin, is a medication used to treat nerve pain and seizures, which may be relevant in the context of the patient's treatment.)\n##\n(\"relationship\"<|>CORTISOL<|>ACTH<|>Cortisol production is stimulated by ACTH, indicating a direct relationship between these two hormones<|>9)\n##\n(\"relationship\"<|>HIDROCORTISONA<|>CORTISOL<|>Hydrocortisone is a synthetic form of cortisol used in treatment, indicating a relationship between the two<|>8)\n##\n(\"relationship\"<|>IGF-1<|>HIDROCORTISONA<|>IGF-1 levels may be measured to assess the effectiveness of hydrocortisone treatment in patients with hormone deficiencies<|>6)\n##\n(\"relationship\"<|>NEURONTIN<|>HIDROCORTISONA<|>Neurontin is used in conjunction with hydrocortisone to manage the patient's symptoms, indicating a relationship<|>5)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: química de insuficiencia suprarrenal secundaria y lo                                                y no parece que la clínica de la paciente vaya a mejorar por aumentar la dosis a 30 mg/día si\n        fundamental será confirmar este diagnóstico e iniciar el tratamiento.                                                                       no hay una situación de estrés que lo justifique (respuesta A falsa).\n          A diferencia de los ejes tiroideo, gonadal y lactotropo, que solo suelen requerir determinaciones                                         Los glucocorticoides de vida media más prolongada como la prednisona o la dexametaso-\n          basales para el diagnóstico de los correspondientes déficits, los ejes somatotropo y corticotropo                                         na no se recomiendan en estos casos, ya que no simulan el ritmo circadiano, tienen riesgo\n          precisan habitualmente de pruebas funcionales dinámicas para evaluar la reserva hipofisaria.                                              de sobredosificación y una gran variabilidad inter- e intraindividuo. Solo se utilizan en pa-\n        Las cifras de cortisol entre 3,6 y 18 µg/dl exigen la confirmación con un test de estímulo y,                                               cientes con muy mal cumplimiento por administrarse en dosis única (respuesta C falsa).\n        de todas las opciones, la única prueba funcional para evaluar el eje corticotropo es el corti-                                              La asociación al tratamiento de mineralcorticoides solo tendría sentido en la insuficiencia\n        sol tras hipoglucemia insulínica (respuesta A). La ACTH basal no permitiría la confirmación                                                 suprarrenal primaria, ya que la regulación de la secreción de aldosterona no depende de la\n        del déficit y, por tanto, quedaría descartada como prueba más útil (respuesta C).                                                           ACTH, sino de la renina-angiotensina. Como este es un caso de insuficiencia suprarrenal\n        La determinación         de   IGF1   y  la de Ac. anti-TPO        podrían aportar        información interesante                            secundaria, la respuesta B es falsa.\n        sobre el estado del eje somatotropo o la presencia de autoinmunidad, pero no van a ser                                                      Por tanto, lo que debemos sospechar ante la falta de respuesta clínica de la pa-\n        la prueba clave en este momento, en el que lo fundamental es confirmar la insuficiencia                                                     ciente a la sustitución con hidrocortisona es que puede tener otros déficits hipofi-\n        suprarrenal secundaria (respuestas B y D).                                                                                                  sarios además del de ACTH y habría que valorar el resto de las hormonas (respues-\n        Sin embargo, aunque el cortisol tras hipoglucemia insulínica es, de todas las opciones, la                                                  ta D correcta).\n        prueba más fiable para valorar la reserva hipofisaria de ACTH, está contraindicada en pa-                                                   Referencias:\n        cientes ancianos, con cardiopatía isquémica o con antecedentes de epilepsia. Quizá nues-                                                    • López-Fernández J, Oliva García JG, Pérez Luis JM. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de\n        tra paciente con antecedentes de crisis de ausencia sería preferiblemente candidata a otro                                                    Endocrinología y Nutrición; 2015. Capítulo 17. Hipopituitarismo [citado 29 de abril de 2019]. Disponible en: https://manual.seen.es/\n                                                                                                                                                      article?id=55114b66-489c-4c70-8a67-2bcdac18103c\n        tipo de prueba funcional del eje corticotropo, como el estímulo con ACTH.\n        Referencias:\n        • López-Fernández J, Oliva García JG, Pérez Luis JM. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de\n          Endocrinología y Nutrición; 2015. Capítulo 17. Hipopituitarismo [citado 29 de abril de 2019]. Disponible en: https://manual.seen.es/\n          article?id=55114b66-489c-4c70-8a67-2bcdac18103c\n\n\n\n72                                                                                                                                                                                                                                                                               73\n---\n                                                                                                                                                                                                                                    HIPÓFISIS                         1\n\n\n\n    61  Desde el tratamiento con hidrocortisona, la paciente no ha vuelto a presentar crisis                                                62  Finalmente la paciente es diagnosticada de déficit de hormona de crecimiento.\n        de ausencia, manteniendo el tratamiento con neurontín. A pesar de haber                                                                 El objetivo fundamental para el tratamiento con GH es:\n        aumentado la dosis de hidrocortisona a 30 mg/día contemplando estrés en el trabajo,                                                     A. Mejorar la capacidad vital y la recuperación después del ejercicio.\n        la situación clínica es la misma. ¿Cuál sería el siguiente paso que definiría mejor la\n        situación?                                                                                                                              B. Mejorar la osteoporosis.\n                                                                                                                                                C. Normalizar los niveles de IGF-1.\n        A. Medir IGF-1.                                                                                                                         D.  Reducir la mortalidad a\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>LOPEZ-FERNANDEZ J<|>PERSON<|>López-Fernández J is an author of the Manual de Endocrinología y Nutrición, which discusses various endocrine disorders and treatments.)\n##\n(\"entity\"<|>OLIVA GARCIA JG<|>PERSON<|>Oliva García JG is an author of the Manual de Endocrinología y Nutrición, contributing to the understanding of endocrine and nutritional issues.)\n##\n(\"entity\"<|>PEREZ LUIS JM<|>PERSON<|>Pérez Luis JM is an author of the Manual de Endocrinología y Nutrición, providing insights into hormonal deficiencies and treatments.)\n##\n(\"entity\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Manual de Endocrinología y Nutrición is a comprehensive guide published by the Sociedad Española de Endocrinología y Nutrición, covering various aspects of endocrinology and nutrition.)\n##\n(\"entity\"<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Sociedad Española de Endocrinología y Nutrición is a professional organization focused on the study and advancement of endocrinology and nutrition in Spain.)\n##\n(\"entity\"<|>HIPOFISIS<|>GEO<|>The hipofisis, or pituitary gland, is a crucial endocrine gland that regulates various hormonal functions in the body.)\n##\n(\"entity\"<|>INSUFICIENCIA SUPRARRENAL SECUNDARIA<|>EVENT<|>Insuficiencia suprarrenal secundaria is a medical condition characterized by insufficient production of hormones from the adrenal glands, often requiring diagnosis and treatment.)\n##\n(\"relationship\"<|>LOPEZ-FERNANDEZ J<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>López-Fernández J is one of the authors of the Manual de Endocrinología y Nutrición, contributing to its content<|>8)\n##\n(\"relationship\"<|>OLIVA GARCIA JG<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Oliva García JG is one of the authors of the Manual de Endocrinología y Nutrición, contributing to its content<|>8)\n##\n(\"relationship\"<|>PEREZ LUIS JM<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Pérez Luis JM is one of the authors of the Manual de Endocrinología y Nutrición, contributing to its content<|>8)\n##\n(\"relationship\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>The Manual de Endocrinología y Nutrición is published by the Sociedad Española de Endocrinología y Nutrición, indicating a professional affiliation<|>9)\n##\n(\"relationship\"<|>INSUFICIENCIA SUPRARRENAL SECUNDARIA<|>HIPOFISIS<|>Insuficiencia suprarrenal secundaria is related to the function of the hipofisis, as it involves hormonal regulation<|>7)\n<|COMPLETE|>"}]}